Related Experiment Video

Updated: Jul 15, 2026

Measuring Deformability and Red Cell Heterogeneity in Blood by Ektacytometry
09:12

Measuring Deformability and Red Cell Heterogeneity in Blood by Ektacytometry

Published on: January 12, 2018

Effects of erythropoietin on erythrocyte deformability in non-transfused preterm infants

Martina Klipp1, Anne-Ulrike Holzwarth, Johannes M Poeschl

  • 1Division of Neonatology, Department of Paediatrics, University of Heidelberg, Germany. KlippMartina@med.uni-heidelberg.de

Acta Paediatrica (Oslo, Norway : 1992)
|April 13, 2007
PubMed

Insights

Recombinant human erythropoietin (rhEPO) treatment significantly improved erythrocyte deformability in preterm infants, reducing anaemia of prematurity. This suggests rhEPO promotes the formation of younger, more adaptable red blood cells.

Area of Science:

  • Neonatal Medicine
  • Hematology
  • Pediatric Anemia Research

Background:

  • Anemia of prematurity is linked to suppressed erythropoiesis.
  • Recombinant human erythropoietin (rhEPO) is used to treat preterm infants.
  • The effect of rhEPO on erythrocyte deformability in this population requires further investigation.

Purpose of the Study:

  • To assess the impact of rhEPO treatment on erythrocyte deformability in preterm infants.
  • To determine if rhEPO improves the physical properties of red blood cells in premature neonates.

Main Methods:

  • A prospective, randomized controlled study involving 31 preterm infants.
  • Treatment group received rhEPO (250 IU/kg three times weekly for 15 doses).
  • Erythrocyte deformability was measured using a shear stress diffractometer, alongside hematological parameters.

Main Results:

  • rhEPO treatment led to significantly higher hemoglobin levels and reticulocyte counts.
  • Erythrocyte deformability, indicated by erythrocyte elongation, was significantly increased in the rhEPO group.
  • A strong correlation was observed between erythrocyte elongation and reticulocyte count.

Conclusions:

  • rhEPO effectively stimulates erythropoiesis in preterm infants, mitigating anemia.
  • rhEPO treatment enhances erythrocyte deformability in preterm infants.
  • Improved erythrocyte deformability is attributed to the generation of young, highly deformable erythrocytes.
Abstract

More Related Videos

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry08:23

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo08:53

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

Published on: January 10, 2025

Related Concept Videos

Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Structure and Function of Erythrocytes01:29

Structure and Function of Erythrocytes

There are between 4.2 and 6 million erythrocytes, also known as red blood cells, in every microliter of blood. These cells are small, flattened biconcave discs with centers that are depressed.
The erythrocyte plasma membrane is associated with proteins such as spectrin, which forms a flexible cytoplasmic meshwork. This meshwork allows erythrocytes to twist, turn, become cup-shaped, and regain their biconcave shape as they pass through narrow capillaries. Additionally, erythrocytes can form...
Lifecycle of Erythrocytes01:22

Lifecycle of Erythrocytes

Erythrocytes, also known as red blood cells, constantly move through blood capillaries. As a result, they damage their plasma membrane due to the continuous friction. Typically, after 100 to 120 days, erythrocytes become rigid and fragile as they wear out. As they pass through small vessels in the spleen and liver, they can get trapped and break apart into fragments.
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups.